Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02439775 · ClinicalTrials.gov registry record · NA
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 337
- Enrollment target
NCT02439775 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 337 participants.
The verdict
NCT02439775, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 337 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.
Interventions
- PROCEDURE Sham Procedure
- DEVICE Symplicity Spyral™ multi-electrode renal denervation system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2015-07-22 |
| Est. Completion | 2025-08-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02439775
The ClinicalTrials.gov registry entry for NCT02439775 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 337 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Procedure is the first listed.
NCT02439775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02439775 about?
NCT02439775 is a clinical study titled "SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System". The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.
What is the current status of trial NCT02439775?
This trial is currently completed. It is a NA study. The enrollment target is 337 participants. The study started on 2015-07-22. Estimated completion is 2025-08-14.
What interventions are being tested in trial NCT02439775?
The interventions under investigation include: Sham Procedure (PROCEDURE), Symplicity Spyral™ multi-electrode renal denervation system (DEVICE).
Who is sponsoring clinical trial NCT02439775?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.